|
Clarient Introduces Mammostrat Test to Quantify Likelihood of Breast Cancer Recurrence |
|
Thursday, 09 December 2010 |
9. December 2010 07:08 - Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the likelihood of recurrence of breast cancer following surgery and initial treatment.The Mammostrat test employs an optimal set of five biomarkers that are able to be identified visually on a patient's tumor specimen by using a well-established technology called immunohistochemistry. Those biomarkers are then analyzed using a mathematical algorithm to generate an assessment of risk for cancer recurrence. Mammostrat is well-validated, having been clinically studied on more than 3,000 women, as reported in multiple peer-reviewed journals, including Breast Cancer Research (Volume 12, 2010), Clinical Cancer Research (Volume 14, October 2006), and the Journal of Clinical Oncology (Volume 24, July 2008). Data from Mammostrat trials have also been presented at national conferences, including the American Society of Clinical Oncology (ASCO) and the San Antonio Breast Cancer Symposium. |
|
Key Findings on Plasma Cell Disorders to be Presented at American Society of Hematology Meeting |
|
Wednesday, 08 December 2010 |
4. December 2010 00:12 -Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, announced that Dr. Raul Braylan, Hematopathologist and Clinical Medical Director of Hematopathology Services, will present key findings related to plasma cell disorders at the upcoming 52nd Annual Meeting and Exposition of the American Society of Hematology. Dr. Braylan will present data validating the clinical utility of Caris' approach to flow cytometric analysis in the routine diagnostic evaluation of patients with plasma cell disorders, such as multiple myeloma.The recent findings confirm that incorporating flow cytometric analysis of bone marrow specimens for abnormal plasma cells, followed by enriched fluorescence in-situ hybridization (FISH) analysis, more effectively detects plasma cell disorders. Plasma cells are antibody-producing lymphoid cells that can develop a variety of plasma cell disorders and may become cancerous. |
|
|
Mysteries of the Blue Ocean |
|
Wednesday, 08 December 2010 |
|
29 November 2010 -Scientists used to think the open ocean was a watery desert. Now we're starting to understand the diversity of life there and the profound influence it has on our climate. Types of plankton that were once dismissed turn out to play a vital role in the carbon cycle. Dave Scanlan and Mike Zubkov explain. Life in the oceans evokes a plethora of images - from whales and shoals of tropical fish to spectacular coral reefs and even monsters of the deep. But although these might be the most amazing and colourful of marine spectacles, it is the abundant microscopic life beneath the waves that ultimately drives all the biogeochemical cycles of the oceans and hence of our planet. The sunlit portion of the ocean, the so-called photic zone, is where carbon is 'fixed' - turned into an organic form that living things can use - by photosynthesis, so it is critical to the global carbon cycle. At the core of the marine food chain tiny phytoplankton, fated to move around the globe at the whim of ocean winds and currents, are the major fixers of carbon dioxide (CO2), levels of which have increased markedly over the last 100 years because of human emissions. To get an idea of how important these organisms are on a global scale, remember that 40 per cent of the CO2 fixed on Earth occurs in marine systems, and 75 per cent of this is fixed in the open ocean.
|
|
|
Centenary Institute Launches New BD LSR-9 Flow Cytometer With Nine Lasers for Studies of Rare Cells |
|
Wednesday, 24 November 2010 |
|
24. November 2010 - A world-first research system to be launched today at the Centenary Institute will give medical researchers in Australia a new weapon in the fight against cancer and other life-threatening diseases. The new BD LSR-9 Flow Cytometer with its nine lasers will be the first user-operated flow cytometer with unprecedented ability to detect and analyse rare cells. The BD LSR9 Flow Cytometer will be housed at the Centenary Institute as part of the Advanced Cytometry Facility (ACF), which is a joint venture run by the Centenary Institute, the University of Sydney and the Bosch Institute. Advanced Cytometry Facility Academic Director Professor Nick King said: "Currently, a researcher may have to run a sample of cells two or three times using complex labelling systems to analyse all the unique characteristics of a cell. This makes it very difficult to detect rare cell populations. It's like a detective at a crime scene gathering two or three sets of partial fingerprints then having to cobble them together to get a complete fingerprint.
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
